Paris, 03rd June 2025 – The global Transcatheter Aortic Valve Implantation (TAVI) market is projected to expand from USD 6.24 billion in 2024 to USD 13.12 billion by 2031, with an anticipated CAGR of 11.2%, according to Clearview Market Insights (CVMI).
“TAVI’s clinical and economic value is clear—it enables faster recovery, lower ICU burden, and increasingly, safer treatment for low-risk patients,” said Dr. Frederik Lange, CVMI’s Director of Structural Heart Devices.
For the full report and data tables, visit: https://clearviewmarketinsights.com/report-details/global-transcatheter-aortic-valve-implantation-tavi-market/
Growth Drivers
- Aging demographics – Aortic stenosis cases rising with population age.
- Expanded clinical use – Low-risk patients now eligible in major markets.
- Faster recovery profile – Drives hospital interest in TAVI over open surgery.
- Ongoing innovation – Valve design improvements increase precision and safety.
- Favorable reimbursement – Medicare and public health systems supporting TAVI in >25 countries.
Market Segmentation
By Valve Type (2024 Share)
- Balloon-Expandable – 49 %
- Self-Expanding – XX %
- Mechanically Expandable – XX %
By Access Route
- Transfemoral – XX %
- Transapical/Others – XX %
By End User
- Hybrid-OR Hospitals – 56 %
- Cardiac Centers – XX %
- Academic Sites – XX %
Transfemoral delivery remains dominant, with adoption rising in ambulatory and day-case cardiac centers. Balloon-expandable valves continue to lead, though self-expanding devices are gaining ground in high-volume centers.
Competitive Landscape
Edwards Lifesciences holds the top position with a 35% share due to its SAPIEN platform. Medtronic, with a 32% share, is gaining momentum through the Evolut FX expansion and global trials. Boston Scientific has returned to the market with LOTUS Edge after its redesign. Abbott and emerging players from China and India complete the expanding field.
Regional Outlook
- North America – Mature market with Medicare coverage and strong TAVI infrastructure.
- Europe – National programs support valve therapy access; low-risk expansion underway.
- Asia-Pacific – Fastest regional growth; Japan and China scale rapidly.
- Latin America & MEA – Public-private TAVI pilots and infrastructure investments increasing access.
Recent Innovations
Repositionable delivery platforms – Minimise valve misplacement.
Low-profile catheters – Allow access in patients with smaller arteries.
AI-enhanced imaging – Supports better planning and intra-op guidance.
Durable polymers – Under study for longer-lasting leaflet materials.
Market Outlook to 2031
- 2026 – Self-expanding valves reach 50 % adoption in academic centers.
- 2027 – TAVI procedures surpass 450,000 annually.
- 2028 – Day-case TAVI becomes viable in 25 % of centers globally.
- 2029 – AI-based sizing tools become standard of care.
- 2030 – Valve durability data exceeds 15 years for major platforms.
- 2031 – TAVI becomes first-line option for 70 % of symptomatic aortic stenosis patients.
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
